Scancell Holdings Plc · LSE:SCLP

Scancell — Shareholder Meeting (October 2017)

14 slides from Scancell's shareholder meeting presentation, Oct 10, 2017

  1. Slide 1: A New Frontier in T-Cell Activation and Targeting

    A NEW FRONTIER IN T-CELL ACTIVATION AND TARGETING AGM PRESENTATION October 10th 2017 Dr John Chiplin: Executive Chairman Dr Richard Goodfellow: CEO Professor Lindy Durrant: CSO LSE: SCLP.L

  2. Slide 2: Disclaimer

    DISCLAIMER Neither the Company nor Panmure, nor any adviser or person acting on their behalf, shall (without prejudice to any liability for fraudulent misrepresentation) have any liability whatsoever for loss however arising, directly or indirectly, from the use of information or opinions communicat

  3. Slide 3: Broad Immuno-Oncology Pipeline

    BROAD IMMUNO-ONCOLOGY PIPELINE 2 PLATFORMS, 3 PRODUCTS, 5 CANCER INDICATIONS  Two disruptive immuno-oncology platforms delivering potent killer T cells without serious side effects  Three lead products addressing five high value disease areas  Moditope® platform overcomes immunosuppression and de

  4. Slide 4: Strong Progress on All Fronts

    STRONG PROGRESS ON ALL FRONTS  Landmark 5-year survival achieved in resected SCIB1 melanoma patients (90% survival including seven patients alive after 5 years)  Production and release of new GMP batch of SCIB1 successfully completed with gold- standard manufacturer  IND application for SCIB1 Pha

  5. Slide 5: The Moditope Platform

    THE MODITOPE® PLATFORM A NOVEL IMMUNOTHERAPY THAT OVERCOMES IMMUNOSUPPRESSION AND DELIVERS UNPRECEDENTED KILLER T-HELPER CELL RESPONSES  Post-translational modifications of proteins occur under conditions of cellular stress  One such modification involves the process of CITRULLINATION  Involves t

  6. Slide 6: Mode of Action

    MODE OF ACTION CITRULLINATED PEPTIDES (MODITOPE®) ACTIVATE KILLER T-HELPER CELLS THAT SEEK AND DESTROY CANCER CELLS  Citrullinated tumour-associated peptides  Primed CD4+ killer T-cells enter the circulation (Moditope peptides) are administered with  Stressed tumour cells undergo autophagy and pr

  7. Slide 7: Wild-Type Peptides Do Not Induce an Anti-Tumour Response

    WILD-TYPE PEPTIDES DO NOT INDUCE AN ANTI-TUMOUR RESPONSE  Citrullinated vimentin and enolase peptides induced high levels of IFNγ-secreting T cell responses in mice  Potent anti-tumour responses induced in mice with established melanoma (B16 iDR4, iDP4), ovarian (ID8-DP4), pancreatic (Pan02-DR4) a

  8. Slide 8: Modi-1

    MODI-1 Vimentin Citrullinated Enolase PAD2 PAD4 Ambra- P62 vimentin autophagy autophagy  Vimentin and/or enolase targets, PADs and autophagy are highly expressed in triple negative breast cancer (90%), ovarian cancer (95%), renal cancer and sarcoma (100%)  Citrullinated vimentin is highly expresse

  9. Slide 9: Moditope Responses in Cancer Patients & Normal Donors

    MODITOPE® RESPONSES IN CANCER PATIENTS & NORMAL DONORS Samples from cancer patients tested in proliferation assay against citrullinated peptides  8/23 patients respond to Vim415cit (Vim-1)  8/23 patients respond to to Vim28cit (Vim-2)  5/23 patients respond to both Vim415cit and Vim28cit Samples

  10. Slide 10: Modi-1 Phase 1/2 Clinical Trial

    MODI-1 PHASE 1/2 CLINICAL TRIAL EXPANSION PHASE 12 Considered worthy of Sarcoma further study if ≥3 RECIST responses in sample size DOSE ESCALATION of 12 12 Dosing regime 9 (up to 15) Ovarian Dose escalation: 10, 50, 250 µg Weeks 1, 3, 6, 12 and 24 Patients may continue to 3 + 3 design receive Modi-

  11. Slide 11: Healthcare Challenge

    HEALTHCARE CHALLENGE TREATMENT OF ADVANCED, SOLID TUMOURS WHERE UNMET MEDICAL NEED FOR IMPROVED THERAPIES PERSISTS  High mortality rate associated with cancer remains despite introduction of checkpoint inhibitors (CPI)  ‘Hot’ tumours with dense T cell infiltrate respond to CPI better than ‘cold’ t

  12. Slide 12: Patents

    PATENTS  European patent for citrullinated peptides for treatment of cancer about to be awarded  Divisional filed for nucleic acid vaccines  Divisional filed for the use of Moditope® T cell receptors for adoptive T cell therapy  Patents in other jurisdictions being examined  Patent filed on cit

  13. Slide 13: Summary

    SUMMARY  Moditope induces potent CD4 T cell responses that do not require CD8 T cells or checkpoint blockade to mount strong anti-tumour responses in bulky tumours  Lead product Modi-1 (three citrullinated peptides linked to a potent and novel adjuvant) defined and ready for further development 

  14. Slide 14: Thank you

    Thank you A NEW FRONTIER IN T-CELL ACTIVATION AND TARGETING 14 14

Scancell Holdings — Shareholder Meeting (October 2017) on 6ix